Sellas Life Sciences Group Inc. (SLS)
NASDAQ
Closed
Aug 24, 2026
Day's Range
13.9152 wk Range
1.39Overview - SLS - Sellas Life Sciences Group Inc.
Key Statistics
Valuation
Enterprise Value
2.98B
P/E (Trailing)
‪-57.31‬
P/E (Forward)
‪-141.50‬
PEG Ratio
‪2.00‬
Price / Book
‪23.90‬
EV / EBITDA
‪-105.55‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-23.29%‬
Return on Equity
‪-39.63%‬
Ownership
Shares Outstanding
181.33M
Float
201.14M
Short % of Shares Outstanding
‪28.07%‬
Held by Insiders
‪0.92%‬
Held by Institutions
‪36.75%‬
Price stats
Beta
‪2.49‬
50-Day Avg
‪11.70‬
200-Day Avg
‪6.18‬
Dividends
Payout Ratio
‪0.00%‬
Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - SLS - Sellas Life Sciences Group Inc.
Peers - SLS - Sellas Life Sciences Group Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- SLSNASDAQSellas Life Sciences Group Inc.2.49BMarket Cap+87.45%52-week change-49.40P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt62.93BMarket Cap+33.08%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.58BMarket Cap-87.93%52-week change40.23P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE29.28BMarket Cap+9.87%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+23.98%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.93BMarket Cap+41.98%52-week change-21.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.27P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - SLS - Sellas Life Sciences Group Inc.
About
Sellas Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy that targets the Wilms tumor 1 (WT1) protein and addresses hematologic…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
